Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome

 

Dr. Hans Bjornsson and colleagues have demonstrated that after treatment with the histone deacetylase inhibitor AR-42 (an anti-cancer drug) the mice models showed a decrease in deficits indicative of hippocampal memory dysfunction. More research is needed, but the results suggest a future possiblity for treatment of certain aspects of intellectual disability in Kabuki.

Files: